Table 1.
Demographics and clinical characteristics at baseline
| With MTX | Without MTX | All adalimumab | |
|---|---|---|---|
| (N = 20) | (N = 5) | (N = 25) | |
| Age | |||
| Mean (SD), years | 13.2 (3.22) | 12.6 (4.39) | 13.0 (3.38) |
| 4–12 years, n (%) | 9 (45) | 3 (60) | 12 (48) |
| 13–17 years, n (%) | 11 (55) | 2 (40) | 13 (52) |
| Female, n (%) | 15 (75) | 5 (100) | 20 (80) |
| Body weight | |||
| Mean (SD), kg | 40.5 (11.28) | 35.3 (16.64) | 39.5 (12.31) |
| ≥30 kg, n (%) | 14 (70) | 3 (60) | 17 (68) |
| Duration of JIA, mean (SD), years | 4.8 (3.97) | 4.2 (2.75) | 4.7 (3.72) |
| RF positive, n (%) | 14 (70) | 3 (60) | 17 (68) |
| Anti-CCP antibody, mean (SD), U/mL | 105.5 (135.67) | 8.5 (15.50) | 86.1 (127.19) |
| LOM69, mean (SD) | 8.6 (5.65) | 5.8 (2.05) | 8.0 (5.22) |
| AJC73, mean (SD) | 12.0 (6.10) | 13.6 (9.32) | 12.3 (6.66) |
| CRP concentration | |||
| Abnormal (>0.3 mg/dL), n (%) | 11 (55) | 3 (60) | 14 (56) |
| Mean (SD), mg/dL | 1.0 (1.32) | 3.6 (3.86) | 1.5 (2.22) |
| CHAQ (0–3), mean (SD) | 0.8 (0.79) | 0.7 (1.11) | 0.8 (0.84) |
| PhGA (0–100 mm), mean (SD) | 56.5 (18.49) | 58.6 (25.83) | 56.9 (19.56) |
| PaGA (0–100 mm), mean (SD) | 44.6 (24.84) | 48.6 (34.20) | 45.4 (26.19) |
AJC active joint count, CCP cyclic citrullinated protein, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, JIA juvenile idiopathic arthritis, LOM limitation of motion, MTX methotrexate, PaGA Patient’s Global Assessment, PhGA Physician’s Global Assessment, RF rheumatoid factor, SD standard deviation